Diabetyping & lifestyle as a medicine
- Conditions
- Type 2 diabetes
- Registration Number
- NL-OMON29401
- Lead Sponsor
- TNO
- Brief Summary
not applicable
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 16
Patient is newly diagnosed with T2D
-Patient is about to start Metformin
-Patient is about to start with a second oral drug (like SU-derivates)
-Patient is about to start with an injectable drug (Insulin or GLP-1)
Besides that, the patients should meet the following inclusion criteria:
-Aged between 30-80 years
-Have a BMI between 25-35 kg/m-2
-Willing and able to sign the informed consent form
-Able to fill in the 360-degree questionnaire which is in Dutch
-Able to work with computers (e.g. for filling out questionnaires).
-Dialysis patients
-Possible limiting personal circumstances (e.g. unemployed, illness in the family, dept restructuring)
-Patients under treatment of a psychiatrist
-Incapacitated patients
-Patients in a palliative phase
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcomes of this study are process variables related to the organizational and financial feasibility of implementation within primary care: time of primary caregivers, costs of medication and facilities and benefits for patients by lower health care use on the longer term.
- Secondary Outcome Measures
Name Time Method The secondary outcomes are related to (change in) health status of participants. First, changes in diabetes related markers such as HbA1c, glucose and insulin will be evaluated descriptively. Several indices can be derived from an OGGT and can indicate organ-specific effects of a distorted glucose tolerance. With these indices several subtypes of diabetes can be distinguished.